Guggenheim Sticks to Their Hold Rating for HCA Healthcare (HCA)

In a report released yesterday, Jason Cassorla from Guggenheim maintained a Hold rating on HCA Healthcare. The company’s shares closed yesterday at $505.84.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Cassorla is an analyst with an average return of -4.2% and a 47.83% success rate. Cassorla covers the Healthcare sector, focusing on stocks such as Universal Health, Cigna, and Acadia Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HCA Healthcare with a $516.46 average price target, a 2.10% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $540.00 price target.

Based on HCA Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $19.51 billion and a net profit of $1.88 billion. In comparison, last year the company earned a revenue of $18.29 billion and had a net profit of $1.44 billion

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Most recently, in November 2025, Michael R McAlevey, the EVP & Chief Legal & Admin Off of HCA sold 3,892.00 shares for a total of $1,843,990.68.